GlassScriptPhysician profile
Camille Buonocore
NPI 1760487797
$487.05
in general payments reported to CMS, 2019-2025
10 companies · $20.34 in 2025
The $20.34 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2022: $61.67 · 2023: $169 · 2024: $117 · 2025: $20.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $306.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $118.64 | 2019 | |
| Abbott Laboratories | $105.27 | 2022-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $69.48 | 2023-2024 | Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $62.54 | 2022-2024 | Ozempic, Rybelsus |
| Amgen INC. | $36.23 | 2023 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $26.97 | 2023 | |
| Horizon Therapeutics Plc | $24.09 | 2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $16.57 | 2023 | |
| Dexcom, INC. | $14.93 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Buonocore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.